Cytiva’s acquisition of CEVEC Pharmaceuticals strengthens the company’s cell line development and biomanufacturing capabilities. Cytiva has acquired CEVEC Pharmaceuticals, a Germany-based provider of ...

Still flying high on a $1.5 billion investment from its parent company, the Danaher Group, Cytiva has acquired a facility in Muskegon, Mich., which it will transform into a manufacturing site for ...

Biopharma’s ongoing quest to develop COVID-19 drugs and vaccines, plus growing industry demand for producing various types of new therapies, are fueling the $1.5-billion expansion of manufacturing ...

Viral vector manufacturing and cell line development are keystone technologies in the making of gene therapies 46 scientific experts based in Cologne, Germany, join the Cytiva team in the genomic ...